

Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Medicine Supply Notification: Progesterone (Lutigest®) 100mg vaginal tablets Progesterone (Crinone®) 8% progesterone vagina gel

Tier 2 – medium impact*

Date of issue: 03/10/2023

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Progesterone (Lutigest®) 100mg vaginal tablets are out of stock until late December 2023.
- Progesterone (Crinone®) 8% progesterone vagina gel is out of stock from late August until late December 2023.
- Alternative progesterone products remain available and will be able to support an increased demand.

Actions Required

Where patients have insufficient supplies to last until the re-supply date, prescribers should:

- consider prescribing alternative progesterone products for supplementation of luteal phase as part of Assisted Reproductive Technology (ART), ensuring that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose required (see Supporting Information below);
- consider alternative management options where the above option is inappropriate and for the indication of use as an adjunct to In Vitro Fertilisation (IVF) where infertility is mainly due to tubal, idiopathic or endometriosis linked sterility associated with normal ovulatory cycles (see Supporting Information below);

Supporting Information

Clinical Information

Lutigest® 100mg vaginal tablets are used for the supplementation of luteal phase as part of Assisted Reproductive Technology (ART). The recommended dose is 100mg administered vaginally three times starting at oocyte retrieval and continued for 30 days if pregnancy has been confirmed.

Crinone® 8% vaginal gel is used for treatment of infertility due to inadequate luteal phase and for use as an adjunct to In Vitro Fertilisation (IVF) where infertility is mainly due to tubal, idiopathic or endometriosis linked sterility associated with normal ovulatory cycles. For the former indication the recommended dose is one applicatorful applied once daily after ovulation or on the 18th to 21st day of the cycle. When used in IVF, it is applied daily starting on the day of embryo transfer and it should be continued for 30 days if there is laboratory evidence of pregnancy

Alternate progesterone products and recommended doses for the supplementation of luteal phase as part of ART:

Cyclogest® 200mg and 400mg pessaries:

- 400mg twice daily vaginally, starting at oocyte retrieval and continuing for 38 days once pregnancy is confirmed

Utrogestan® 200mg vaginal capsules:

- 200mg three times daily from day of embryo transfer until at least week 7 of pregnancy up to week 12 of pregnancy

Lubion® 25mg/1.112ml solution for injection vials (in women for whom vaginal preparations are inappropriate):

- 25mg injected subcutaneously or intramuscularly from day of oocyte retrieval up to week 12 of pregnancy

Links to further information:

- SmPC Utrogestan 200mg vaginal capsules [Utrogestan Vaginal 200mg Capsules - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#)
- SmPC Cyclogest pessaries [Search Results - \(emc\) \(medicines.org.uk\)](#)
- SmPC Lubion 25mg/1.112ml solution for injection vials [Microsoft Word - 4886246514978474929_spc-doc.doc \(windows.net\)](#)
- SmPC Lutigest 100mg vaginal tablets [Lutigest 100 mg vaginal tablets - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#)
- SmPC Crinone 8% vaginal gel [Crinone 8% Progesterone Vaginal Gel - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#)
- BNF Progesterone [Progesterone | Drugs | BNF | NICE](#)